MX2015011730A - Metodos para tratar la lesion renal aguda. - Google Patents

Metodos para tratar la lesion renal aguda.

Info

Publication number
MX2015011730A
MX2015011730A MX2015011730A MX2015011730A MX2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A
Authority
MX
Mexico
Prior art keywords
methods
kidney injury
kidney
treating acute
acute kidney
Prior art date
Application number
MX2015011730A
Other languages
English (en)
Spanish (es)
Inventor
Richard A Zager
Denni Andress
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015011730A publication Critical patent/MX2015011730A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7019Ischaemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7038Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015011730A 2013-03-08 2014-03-10 Metodos para tratar la lesion renal aguda. MX2015011730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
MX2015011730A true MX2015011730A (es) 2016-04-04

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011730A MX2015011730A (es) 2013-03-08 2014-03-10 Metodos para tratar la lesion renal aguda.

Country Status (10)

Country Link
US (1) US20160015701A1 (enExample)
EP (1) EP2964671A4 (enExample)
JP (1) JP2016512201A (enExample)
CN (1) CN105324395A (enExample)
AU (1) AU2014225320A1 (enExample)
BR (1) BR112015020788A2 (enExample)
CA (1) CA2901922A1 (enExample)
HK (1) HK1220209A1 (enExample)
MX (1) MX2015011730A (enExample)
WO (1) WO2014138738A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909871A1 (en) 2013-04-30 2014-11-06 Abbvie Inc. Methods for improving lipid profiles using atrasentan
MX2017005884A (es) * 2014-11-07 2017-06-26 Abbvie Inc Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
WO2018067857A1 (en) * 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
WO2021091791A1 (en) * 2019-11-06 2021-05-14 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
MX2022007471A (es) * 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
CA2563996A1 (en) * 2004-04-23 2005-11-10 Renal Diagnostic, Inc. An automated non- invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Also Published As

Publication number Publication date
AU2014225320A1 (en) 2015-08-06
BR112015020788A2 (pt) 2017-10-10
EP2964671A1 (en) 2016-01-13
WO2014138738A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30
EP2964671A4 (en) 2016-08-31
CA2901922A1 (en) 2014-09-12
CN105324395A (zh) 2016-02-10
JP2016512201A (ja) 2016-04-25
HK1220209A1 (zh) 2017-04-28
US20160015701A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
MX2015011730A (es) Metodos para tratar la lesion renal aguda.
Martel-Pelletier et al. Future therapeutics for osteoarthritis
FIC20253010I1 (fi) Akalabrutinibi tai sen farmaseuttisesti hyväksyttävä suola, yhdessä venetoklaksin kanssa, valinnaisesti obinututsumabin kanssa tai ilman sitä
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2025022I1 (no) Belzutifan, or a pharmaceutically acceptable salt thereof, particularly belzutifan.
NO2022004I1 (no) abrocitinib, or a pharmaceutically acceptable salt thereof
NO2025017I1 (no) Acoramidis, and/or a pharmaceutically acceptable salt thereof, especially acoramidis hydrochloride
HK1207000A1 (en) Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
BR112015027281A2 (pt) combinações de dosagens para reduzir respostas imunológicas humorais indesejadas
HK1252816A1 (zh) Tlr8激活剂治疗癌症的应用
HK1243430A1 (zh) 通过施用il-6r拮抗剂治疗乾眼病的方法
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
BR112015007749A2 (pt) métodos para tratamento de hipertensão , de hipercaliemia , e de doença renal crônica.
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
BR112015020199A2 (pt) usos terapêuticos para anticorpos de vegfr1
GB201622371D0 (en) Latency reduction in feedback-based system performance determination
GB201319369D0 (en) Voice authentication in transactions
EP2959906A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
EP2959908A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959905A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES
EP2959907A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
PH12017501214A1 (en) Cgrp antagonist peptides
TN2016000233A1 (en) Adenosine a1 agonists as medicaments against renal diseases.